Mustapha El Lakis1, Pavel Nockel1, Bin Guan2, Sunita Agarwal2, James Welch2, William F Simonds2, Stephen Marx2, Yulong Li2, Naris Nilubol2, Dhaval Patel1, Lily Yang1, Roxanne Merkel1, Electron Kebebew3. 1. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Metabolic Disease Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Surgery, The George Washington University, School of Medicine and Health Sciences, Washington, DC. Electronic address: kebebewe@mail.nih.gov.
Abstract
BACKGROUND: Hereditary primary hyperparathyroidism may be syndromic or nonsyndromic (familial isolated hyperparathyroidism). Recently, germline activating mutations in the GCM2 gene were identified in a subset of familial isolated hyperparathyroidism. This study examined the clinical and biochemical characteristics and the treatment outcomes of GCM2 mutation-positive familial isolated hyperparathyroidism as compared to sporadic primary hyperparathyroidism. METHODS: We performed a retrospective analysis of clinical features, parathyroid pathology, and operative outcomes in 18 patients with GCM2 germline mutations and 457 patients with sporadic primary hyperparathyroidism. RESULTS: Age at diagnosis, sex distribution, race/ethnicity, and preoperative serum calcium concentrations were similar between the 2 groups. The preoperative serum levels of intact parathyroid hormone was greater in patients with GCM2-associated primary hyperparathyroidism (239 ± 394 vs 136 ± 113, P = .005) as were rates of multigland disease and parathyroid carcinoma in the GCM2 group (78% vs 14.3%, P < .001 and 5% vs 0%, P = .04, respectively), but the biochemical cure rate was less in the GCM2 group (86% vs 99%, P < .001). CONCLUSION: GCM2-associated primary hyperparathyroidism patients have greater preoperative parathyroid hormone levels, a greater rate of multigland disease, a lesser rate of biochemical cure, and a substantial risk of parathyroid carcinoma. Knowledge of these clinical characteristics could optimize the surgical management of GCM2-associated familial isolated hyperparathyroidism. Published by Elsevier Inc.
BACKGROUND:Hereditary primary hyperparathyroidism may be syndromic or nonsyndromic (familial isolated hyperparathyroidism). Recently, germline activating mutations in the GCM2 gene were identified in a subset of familial isolated hyperparathyroidism. This study examined the clinical and biochemical characteristics and the treatment outcomes of GCM2 mutation-positive familial isolated hyperparathyroidism as compared to sporadic primary hyperparathyroidism. METHODS: We performed a retrospective analysis of clinical features, parathyroid pathology, and operative outcomes in 18 patients with GCM2 germline mutations and 457 patients with sporadic primary hyperparathyroidism. RESULTS: Age at diagnosis, sex distribution, race/ethnicity, and preoperative serum calcium concentrations were similar between the 2 groups. The preoperative serum levels of intact parathyroid hormone was greater in patients with GCM2-associated primary hyperparathyroidism (239 ± 394 vs 136 ± 113, P = .005) as were rates of multigland disease and parathyroid carcinoma in the GCM2 group (78% vs 14.3%, P < .001 and 5% vs 0%, P = .04, respectively), but the biochemical cure rate was less in the GCM2 group (86% vs 99%, P < .001). CONCLUSION:GCM2-associated primary hyperparathyroidismpatients have greater preoperative parathyroid hormone levels, a greater rate of multigland disease, a lesser rate of biochemical cure, and a substantial risk of parathyroid carcinoma. Knowledge of these clinical characteristics could optimize the surgical management of GCM2-associated familial isolated hyperparathyroidism. Published by Elsevier Inc.
Authors: Naris Nilubol; Lee Weinstein; William F Simonds; Robert T Jensen; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Stephen Marx; Electron Kebebew Journal: World J Surg Date: 2012-06 Impact factor: 3.352
Authors: I Schuffenecker; M Virally-Monod; R Brohet; D Goldgar; B Conte-Devolx; L Leclerc; O Chabre; A Boneu; J Caron; C Houdent; E Modigliani; V Rohmer; M Schlumberger; C Eng; P J Guillausseau; G M Lenoir Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: Bin Guan; James M Welch; Julie C Sapp; Hua Ling; Yulong Li; Jennifer J Johnston; Electron Kebebew; Leslie G Biesecker; William F Simonds; Stephen J Marx; Sunita K Agarwal Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Sahzene Yavuz; William F Simonds; Lee S Weinstein; Michael T Collins; Electron Kebebew; Naris Nilubol; Giao Q Phan; Steven K Libutti; Alan T Remaley; Manuel Van Deventer; Stephen J Marx Journal: J Clin Endocrinol Metab Date: 2012-04-16 Impact factor: 5.958
Authors: T Günther; Z F Chen; J Kim; M Priemel; J M Rueger; M Amling; J M Moseley; T J Martin; D J Anderson; G Karsenty Journal: Nature Date: 2000-07-13 Impact factor: 49.962
Authors: Ewa Lundgren; Emil G Hagström; Jonas Lundin; Kajsa Winnerbäck; Johanna Roos; Sverker Ljunghall; Jonas Rastad Journal: World J Surg Date: 2002-06-06 Impact factor: 3.352
Authors: Naris Nilubol; Lee S Weinstein; William F Simonds; Robert T Jensen; Stephen J Marx; Electron Kebebew Journal: Ann Surg Oncol Date: 2015-11-05 Impact factor: 5.344
Authors: F Cetani; E Pardi; P Aretini; F Saponaro; S Borsari; L Mazoni; M Apicella; P Civita; M La Ferla; M A Caligo; F Lessi; C M Mazzanti; L Torregossa; A Oppo; C Marcocci Journal: J Endocrinol Invest Date: 2019-09-05 Impact factor: 4.256